Roll Over StudY for Patients Who Have Completed a Previous Oncology Study with Olaparib - ROSY-O

Study identifier:D0817C00098

ClinicalTrials.gov identifier:NCT04421963

EudraCT identifier:2019-003777-26

CTIS identifier:N/A

Recruiting

Official Title

Roll Over StudY for Patients Who Have Completed a Previous Oncology Study with Olaparib and Are Judged by the Investigator to Clinically Benefit From Continued Treatment

Medical condition

ovarian cancer

Phase

Phase 3

Healthy volunteers

No

Study drug

Olaparib

Sex

All

Estimated Enrollment

267

Study type

Interventional

Age

18 Years - 99 Years

Date

Study Start Date: 04 Aug 2020
Estimated Primary Completion Date: 30 Apr 2025
Estimated Study Completion Date: 30 Apr 2025

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: Sequential Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Sept 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria